Cargando…
Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor
INTRODUCTION: While the acquisition of mutations in the ABL1 kinase domain (KD) has been identified as a common mechanism behind tyrosine kinase inhibitor (TKI) resistance, recent genetic studies have revealed that patients with TKI resistance or intolerance frequently harbor one or more genetic alt...
Autores principales: | Wu, Waner, Xu, Na, Zhou, Xuan, Liu, Liang, Tan, Yaxian, Luo, Jie, Huang, Jixian, Qin, Jiayue, Wang, Juan, Li, Zhimin, Yin, Changxin, Zhou, Lingling, Liu, Xiaoli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468532/ https://www.ncbi.nlm.nih.gov/pubmed/32943879 http://dx.doi.org/10.2147/OTT.S257661 |
Ejemplares similares
-
De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
por: Luo, Jie, et al.
Publicado: (2022) -
Therapeutic immune monitoring of CD4(+)CD25(+) T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
por: Lu, Ziyuan, et al.
Publicado: (2017) -
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
por: DeAngelo, D J
Publicado: (2012) -
Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia
por: Yu, Guopan, et al.
Publicado: (2017) -
Importance of monitoring and early switch to second generation tyrosine
kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with
imatinib resistance or intolerance
por: Simões, Belinda Pinto, et al.
Publicado: (2011)